U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. 22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results
  1. Reports

22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results

Read the full report (PDF- 501 KB)

Summary

To better understand the nature of the evidence obtained from many phase 2 trials and the contributions of phase 3 trials of drugs, vaccines and medical devices, FDA studied 22 recent cases in which promising phase 2 clinical trial results were not confirmed in phase 3 clinical testing. Phase 3 studies did not confirm phase 2 findings of effectiveness in 14 cases, safety in one case, and both safety and effectiveness in seven cases. These unexpected results could occur even when the phase 2 study was relatively large and even when the phase 2 trials assessed clinical outcomes. 

These case studies demonstrate that large phase 3 randomized controlled trials can generate critical evidence across all types of products, patients, and diseases. Both safety and efficacy failures occurred even when the phase 2 studies were relatively large, and even when the product was already approved for another condition. In some cases, the phase 3 study revealed that short-term results found in the phase 2 study were not associated with a long-term benefit or that the product had toxicity that was not uncovered in the phase 2 study. 
 

Back to Top